Lolamicin Explained

Lolamicin is an experimental antibiotic.[1] It targets Gram-negative bacteria without significantly affecting typical gut microbes.[2] Lolamicin was discovered by a team led by Paul Hergenrother at the University of Illinois Urbana-Champaign and was first reported in 2024.[1]

In a mouse model of bacterial infection, lolamicin was found to be especially effective against Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae.[3]

Lolamicin works by interfering with the lipoprotein transport system of Gram-negative bacteria.[1]

Notes and References

  1. 10.1038/s41586-024-07502-0 . A Gram-negative-selective antibiotic that spares the gut microbiome . 2024 . Muñoz . Kristen A. . Ulrich . Rebecca J. . Vasan . Archit K. . Sinclair . Matt . Wen . Po-Chao . Holmes . Jessica R. . Lee . Hyang Yeon . Hung . Chien-Che . Fields . Christopher J. . Tajkhorshid . Emad . Lau . Gee W. . Hergenrother . Paul J. . Nature . 630 . 8016 . 429–436 . 38811738 .
  2. News: 'Smart' antibiotic can kill deadly bacteria while sparing the microbiome . May 29, 2024 . nature.com .
  3. News: New antibiotic targets only gram-negative bacteria, sparing the gut . June 1, 2024 . .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lolamicin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.